Myeloproliferative Disorder Clinical Trial
— MPL - NPMOfficial title:
Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia
Verified date | January 2024 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The MPL gene is implicated in two groups of hematological pathologies: congenital amegakaryocytic thrombocytopenia (CAMT) and Phi negative myeloproliferative neoplasia (MPN). Fifty germline mutations have been identified in CAMT, yet only a dozen activating mutations have been described in MPN. Most are somatic, distributed mainly in the transmembrane (TM) and juxtamembrane (JM) domains. However, a few rare germline mutations located in the extracellular domain (ECD) have also been reported: K39N, R102P and P106L. Next generation sequencing technology has been used to study the complete MPL gene, identifying numerous variants, most of unknown significance. The study investigators have a series comprising 41 variants of unknown significance, whose allelic frequencies suggest a germline origin for 80% of them. Their distribution within the MPL gene is similar to that of inactivating mutations, except that they were discovered in the context of suspected myeloproliferative disease. Characterizing the activity of these variants would confirm the diagnosis of MPN, opening the door to specific treatment (cytoreductive, JAK2 inhibitor or interferon). It also has an important prognostic value, particularly in the case of MPN, for which life expectancy varies from 5 to 7 years, with terminal progression to acute myeloid leukemia (AML in 15 to 20% of cases) or bone marrow failure. Using a battery of functional assays, this study aims to characterize these variants.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | April 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: • Patient with suspected MPN Exclusion Criteria: • Patient with variant of cMPL already described in the literature. |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nîmes | Nîmes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Growth of cultured cells with site-directed mutagenesis of identified variants in the presence of thrombopoietin | Thrombopoietin concentration curve | Day 0 | |
Primary | Ability of cultured cells with site-directed mutagenesis of identified variants to activate the MPL - JAK2 pathway | STAT5 Luciferase reporter system | Day 0 | |
Primary | Ability of cultured cells with site-directed mutagenesis of identified variants to phosphorylate proteins in the MPL - JAK2 pathway | Western blot of JAK2, STAT (3 and 5) AKT, ERK1 /2 proteins | Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT03149055 -
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
|
Phase 2 | |
Completed |
NCT01866839 -
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
|
Phase 1/Phase 2 | |
Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
Completed |
NCT00588666 -
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03480360 -
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
|
Phase 3 | |
Completed |
NCT00539695 -
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
|
Phase 2 | |
Recruiting |
NCT03869476 -
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
|
N/A | |
Completed |
NCT00175838 -
Primary Thrombocythaemia 1 Trial
|
N/A | |
Completed |
NCT03688490 -
Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms
|
||
Active, not recruiting |
NCT03434730 -
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
|
Phase 2 | |
Recruiting |
NCT03852407 -
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
|
Phase 2 | |
Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
Completed |
NCT00533923 -
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
|
Phase 2 | |
Active, not recruiting |
NCT04473911 -
Haplo Peripheral Blood Sct In GVHD Prevention
|
Phase 1 | |
Completed |
NCT00909467 -
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
|
N/A | |
Completed |
NCT00687414 -
Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders
|
||
Recruiting |
NCT03808805 -
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
|
Phase 3 |